Company intelligence / Profile preview

Shanghai Hansoh Biomedicine Technology

Shanghai, Shanghai, China

Ownership: Private
Employees: ~7500
Development stage: Other

Overview

Hansoh currently has over 40 innovative drug candidates with more than 70 clinical trials underway; 7 innovative drugs are approved and marketed, covering oncology, infection, CNS, metabolic, and autoimmune diseases. HS-20093 (B7-H3 ADC) shows promising results in early clinical trials for multiple solid tumors.

Therapeutic areas: NephrologyEndocrinologyInfectious DiseasesDermatologyOncologyNeurology
Modalities: Small moleculeAntibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodyFusion proteinsiRNAPeptidesBiologic
Industry: Biotech

Partnerships

GSK (HS-20093, HS-20089 licensing)MSD (Merck & Co.)Regeneron

Beyond the preview

Go deeper on Shanghai Hansoh Biomedicine Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Hansoh Biomedicine Technology.

Explore the full profile